Expression of HLA class I and HLA class II by tumor cells in Chinese classical Hodgkin Lymphoma patients

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Huang, Xin ^a,b   van den Berg, Anke ^a   Gao, Zifen ^b   Visser, Lydia ^a   Nolte, Ilja ^a   Vos, Hans ^a   Hepkema, Bouke ^a   Kooistra, Wierd ^a   Poppema, Sibrand ^a   Diepstra, Arjan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CANCER ANTIBODY; HLA A1 ANTIGEN; HLA A2 ANTIGEN; VIRUS RNA;

ADULT; AGED; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CHILD; CHINESE; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; HEAVY CHAIN; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; IN SITU HYBRIDIZATION; LYMPHOMA CELL; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRESCHOOL CHILD; SEX DIFFERENCE; TUMOR IMMUNITY; VIRUS DETECTION; VIRUS PATHOGENESIS;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NETHERLANDS; RNA, VIRAL; YOUNG ADULT;

HUMAN HERPESVIRUS 4;

EID: 77956546059     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010865     Document Type: Article

References (19)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (2008) WHO Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
2. de JD, Enblad G (2008) Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med 264: 528-536.
3. Gandhi MK, Tellam JT, Khanna R (2004) Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 125: 267-281.
4. Kuppers R (2009) The biology of Hodgkin's lymphoma. Nat Rev Cancer 9: 15-27.
5. Nakatsuka S, Aozasa K (2006) Epidemiology and pathologic features of Hodgkin lymphoma. Int J Hematol 83: 391-397.
6. Alvaro T, Lejeune M, Garcia JF, Salvado MT, Lopez C, et al. (2008) Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res 14: 685-691.
7. Bryden H, MacKenzie J, Andrew L, Alexander FE, Angus B, et al. (1997) Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein. Int J Cancer 72: 614-618.
8. Voo KS, Fu T, Heslop HE, Brenner MK, Rooney CM, et al. (2002) Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res 62: 7195-7199.
9. Wang RF (2003) Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells. Methods 29: 227-235.
10. Omiya R, Buteau C, Kobayashi H, Paya CV, Celis E (2002) Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol 169: 2172-2179.
11. Diepstra A, Niens M, Vellenga E, van Imhoff GW, Nolte IM, et al. (2005) Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 365: 2216-2224.
12. Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, Te Meerman GJ, et al. (2007) HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 25: 3101-3108.
13. Lee SP, Constandinou CM, Thomas WA, Croom-Carter D, Blake NW, et al. (1998) Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition. Blood 92: 1020-1030.
14. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF (1998) Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 92: 2477-2483.
15. Niens M, Jarrett RF, Hepkema B, Nolte IM, Diepstra A, et al. (2007) HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110: 3310-3315.
16. Oudejans JJ, Jiwa NM, Kummer JA, Horstman A, Vos W, et al. (1996) Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 87: 3844-3851.
17. Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137: 2299-2306.
18. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27: 5869-5885.
19. Diepstra A, Poppema S, Boot M, Visser L, Nolte IM, et al. (2008) HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 71: 219-226.